Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2020
2019
Profitability Metrics
Gross Margin
60.68%
Operating Margin
61.91%
Net Margin
58.11%
Efficiency Metrics
Revenue per Expense Ratio
2.63
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
61.91%
Income Tax Rate
0.00%
EPS
1.7800000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
13.51
Working Capital
$-305.52K
Debt to Equity
0.72
Debt to Assets
41.75%
Equity Ratio
57.68%
Cash Flow Analysis
Operating Cash Flow Ratio
42.29%
Free Cash Flow Ratio
42.29%
CapEx to Revenue
0.00%
Dividends Paid
$6.14M
Stock Buybacks
$14.89M
Total Shareholder Returns
$21.03M
Cash Position Change
0.29%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
62.72%
Net Income
115.16%
EPS
111.90%
Operating Income
129.22%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
12.62%
Operating Cash Flow
81.70%
Free Cash Flow
81.70%
Balance Sheet Health
Assets
6.32%
Debt
4,759.54%
Book Value per Share
-0.96%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-10.89%
Shares Outstanding
1.52%
Long Term Trends
3Y Revenue/Share
-39.19%
5Y Revenue/Share
179.65%
3Y Dividend/Share
-13.59%
5Y Dividend/Share
-0.15%